ERBB2 and breast carcinoma: However, with the development of more potent HER2-directed therapies, such as novel antibody-drug conjugates (ADC), the question about the use of HER2-targeted agents for HER2-low breast cancer re-emerged and gained momentum, particularly after the publication of the results of DESTINY-Breast04 [12].